REGENXBIO Faces A Filing Checkpoint As Royalties Shrink And The Stock Slumps

REGENXBIO heads into its third-quarter report with a striking disconnect. Three months ago management delivered its most confident update in a year: a cleared regulatory path for its Hunter syndrome therapy, a Duchenne program running ahead of schedule and a cash runway pushed a full year further out. The market's answer has been a 36% drop in the shares while the S&P 500 went nowhere. That leaves this report less about the quarterly numbers and more about whether the company can show that the regulatory milestones it promised for the third quarter actually happened.

The numbers themselves will look ugly, and that is expected. Wall Street forecasts a loss of $1.35 per share, wider than the $1.20 loss a year ago, on revenue of roughly $9.6 million, down about 68% from $29.7 million. The comparison with last quarter is even starker, since second-quarter revenue of $108 million and a rare profit of $0.43 per share were driven by a one-time $100 million AbbVie milestone tied to the first patient dosed in the NAVIGATE diabetic retinopathy trial. Without a similar payment, revenue falls back to its royalty base, and that base is now under pressure. Management disclosed last quarter that the U.S. patent covering Zolgensma has expired, which trims domestic royalties. The company pointed to coverage in about 20 countries outside the U.S. plus worldwide protection on another Novartis product as partial offsets, so the royalty line this quarter offers the first clean look at how much the U.S. expiry actually costs. A revenue figure well below consensus would suggest the erosion is steeper than the offsets can absorb.

The more consequential items are the filings. Management said it planned to resubmit the RGX121 application in the third quarter after a July meeting in which the FDA indicated existing data could support accelerated approval without a new randomized trial. That outcome reversed what had looked like a stalled program, so confirmation that the resubmission went in on schedule would validate the improved tone. On Duchenne, the company targeted submission of the first module of the RGX202 application in the third quarter, building on pivotal results that met the primary endpoint and showed a tight link between microdystrophin expression and function, with possible U.S. approval in the second half of 2027. Any slippage on either timeline would cut directly against the narrative that the company is executing ahead of plan. Investors should also listen for how management frames the confirmatory RGX202 study running during review, a lingering uncertainty in how the FDA weighs the package.

Cash is the other anchor. Pro forma cash stood above $310 million after the AbbVie payment and a $108 million equity raise, supporting runway into the fourth quarter of 2027. With operating losses resuming, a reaffirmation of that runway matters more than the size of the quarterly loss, and any trimming would be a red flag.

Sentiment has soured alongside the stock. Readings have grown more bearish since the prior report, and the shares sit at $7.24, well below the 200-day moving average near $9.31 and closer to the post-earnings low of $6.46 than the high of $12.08. That positioning suggests the market is discounting execution risk, and perhaps the binary wet AMD pivotal readout due in the fourth quarter, which carries a 4.5-letter non-inferiority margin.

The central question is simple: did REGENXBIO deliver the two third-quarter filings it promised while holding its runway steady? If so, the gap between an improving pipeline and a sinking share price becomes harder to justify. If not, the bears' skepticism will look well placed heading into the wet AMD data.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.